NRX Pharmaceuticals, Inc. (NRXPW)
2025-06-30 | ||||
|---|---|---|---|---|
| Research and development | 987 | |||
| Settlement expense | - | |||
| General and administrative | 2,743 | |||
| Total operating expenses | 3,730 | |||
| Loss from operations | -3,730 | |||
| Convertible note default penalty | - | |||
| Interest income | 2 | |||
| Interest expense | - | |||
| Change in fair value of warrant liabilities | 6,414 | |||
| Loss on issuance of the registered direct offering (see note 9) | - | |||
| Loss on convertible note conversions | -1,874 | |||
| Loss on consideration shares and warrants (see note 9) | - | |||
| Change in fair value of convertible note payable | 5,565 | |||
| Total other expenses, net | -13,851 | |||
| Net loss | -17,581 | |||
| Basic and diluted (in dollars per share) | -0.98 | |||
| Basic and diluted (in shares) | 17,934,196 | |||